Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
14 "Therapy"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Trends in Physiotherapy Interventions and Medical Costs for Parkinson’s Disease in South Korea, 2011–2020
Dong-Woo Ryu, Jinse Park, Myung Jun Lee, Dallah Yoo, Sang-Myung Cheon
Received December 22, 2023  Accepted March 18, 2024  Published online March 19, 2024  
DOI: https://doi.org/10.14802/jmd.23269    [Accepted]
  • 181 View
  • 12 Download
AbstractAbstract PDF
Objective
Physiotherapy (PT), an effective strategy for managing Parkinson’s disease (PD), can influence healthcare utilization. We analyzed trends in healthcare utilization, PT interventions, and medical costs among patients with PD.
Methods
Using data from the Korean National Health Insurance Service from 2011 to 2020, we analyzed the number of patients with PD and their healthcare utilization and assessed the odds ratio (OR) for receiving regular PTs.
Results
Over 10 years, 169,613 patients with PD were present. The number of patients with PD increased annually from 49,417 in 2011 to 91,841 in 2020. Patients with PD receiving PT increased from 4,847 (9.81%) in 2011 to 13,163 (14.33%) in 2020, and PT prescriptions increased from 81,220 in 2011 to 377,651 in 2019. Medical costs per patient with PD have increased from 1,686 United States Dollars (USD) in 2011 to 3,201 USD in 2020. Medical expenses for each patient with PD receiving PT increased from 6,581 USD in 2011 to 13,476 USD in 2020. Moreover, Regular PTs were administered to 31,782 patients (18.74%) and conducted only through hospitalization. Those in their 50s with disabilities demonstrated a high OR for regular PTs, while those aged 80 years or older and residing outside Seoul had a low OR.
Conclusions
The PD burden increased in South Korea between 2011 and 2020, including an increase in healthcare utilization and medical costs. The significant rise in medical expenses can be associated with increased PD prevalence and PT interventions. Regular PT applications remain restricted and have barriers to access.
Parkinson’s Disease, Impulsive-Compulsive Behaviors, and Health-Related Quality of Life
Marie Grall-Bronnec, Audrey Verholleman, Caroline Victorri-Vigneau, Juliette Leboucher, Elsa Thiabaud, Jean-Benoit Hardouin, Benoit Schreck, Tiphaine Rouaud, Monica Roy, Pascal Derkinderen, Gaëlle Challet-Bouju
J Mov Disord. 2024;17(1):82-88.   Published online November 6, 2023
DOI: https://doi.org/10.14802/jmd.23042
  • 796 View
  • 67 Download
AbstractAbstract PDFSupplementary Material
Objective
A large body of literature has examined the links between the use of dopamine replacement therapy (DRT) in Parkinson’s disease (PD) and the development of “impulsive-compulsive behaviors (ICBs).” Little is known regarding the link between the development of ICBs and health-related quality of life (HRQOL). We aimed to explore the factors that are associated with poorer HRQOL, especially in relation to DRT-induced ICBs, in a sample of PD patients.
Methods
This PARKADD (PARK: PARKinson’s disease; ADD: behavioral ADDictions) study was a prospective case‒control study initially designed to assess the factors associated with ICBs in PD patients. A prospective clinical follow-up was added, aiming to capture the long-term evolution of HRQOL in relation to ICBs occurring or worsening after the beginning of PD. We focused on sociodemographic and PD characteristics and the history or presence of ICBs. HRQOL was measured using the Parkinson’s Disease Questionnaire-8. A multivariate linear regression was performed to identify factors related to poorer HRQOL.
Results
A total of 169 patients were eligible for the follow-up study. The presence of an ICB, a higher levodopa equivalent daily dose (LEDD) and a longer PD duration were significantly associated with poorer HRQOL, with an interaction between LEDD and PD duration.
Conclusion
The presence of an ICB was related to poorer HRQOL and should be considered a crucial factor for the management of PD patients. Several studies were recently published that provide guidelines for the management of these patients, with recommendations based on two key principles: prevention and specific treatment.
Review Articles
Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease
Young Cha, Tae-Yoon Park, Pierre Leblanc, Kwang-Soo Kim
J Mov Disord. 2023;16(1):22-41.   Published online January 12, 2023
DOI: https://doi.org/10.14802/jmd.22141
  • 6,004 View
  • 461 Download
  • 9 Web of Science
  • 8 Crossref
AbstractAbstract PDF
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting 1%–2% of the population over the age of 65. As the population ages, it is anticipated that the burden on society will significantly escalate. Although symptom reduction by currently available pharmacological and/or surgical treatments improves the quality of life of many PD patients, there are no treatments that can slow down, halt, or reverse disease progression. Because the loss of a specific cell type, midbrain dopamine neurons in the substantia nigra, is the main cause of motor dysfunction in PD, it is considered a promising target for cell replacement therapy. Indeed, numerous preclinical and clinical studies using fetal cell transplantation have provided proof of concept that cell replacement therapy may be a viable therapeutic approach for PD. However, the use of human fetal cells remains fraught with controversy due to fundamental ethical, practical, and clinical limitations. Groundbreaking work on human pluripotent stem cells (hPSCs), including human embryonic stem cells and human induced pluripotent stem cells, coupled with extensive basic research in the stem cell field offers promising potential for hPSC-based cell replacement to become a realistic treatment regimen for PD once several major issues can be successfully addressed. In this review, we will discuss the prospects and challenges of hPSC-based cell therapy for PD.

Citations

Citations to this article as recorded by  
  • RNA-based controllers for engineering gene and cell therapies
    Kei Takahashi, Kate E Galloway
    Current Opinion in Biotechnology.2024; 85: 103026.     CrossRef
  • Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells
    Min Seong Kim, Hyesoo Kim, Gabsang Lee
    Advanced Healthcare Materials.2024;[Epub]     CrossRef
  • A recent update on drugs and alternative approaches for parkinsonism
    Sneha Kispotta, Debajyoti Das, Shakti Ketan Prusty
    Neuropeptides.2024; 104: 102415.     CrossRef
  • Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
    Jessica Cohen, Annette Mathew, Kirk D. Dourvetakis, Estella Sanchez-Guerrero, Rajendra P. Pangeni, Narasimman Gurusamy, Kristina K. Aenlle, Geeta Ravindran, Assma Twahir, Dylan Isler, Sara Rukmini Sosa-Garcia, Axel Llizo, Alison C. Bested, Theoharis C. Th
    Cells.2024; 13(6): 511.     CrossRef
  • Continuous immunosuppression is required for suppressing immune responses to xenografts in non-human primate brains
    Su Feng, Ting Zhang, Zhengxiao He, Wenchang Zhang, Yingying Chen, Chunmei Yue, Naihe Jing
    Cell Regeneration.2024;[Epub]     CrossRef
  • Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease
    David J. Rademacher
    Biomedicines.2023; 11(4): 1187.     CrossRef
  • Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases
    Amir Gholamzad, Hadis Sadeghi, Maryam Azizabadi Farahani, Ali Faraji, Mahya Rostami, Sajad Khonche, Shirin Kamrani, Mahsa Khatibi, Omid Moeini, Seyed Armit Hosseini, Mohammadmatin Nourikhani, Mehrdad Gholamzad
    Neurology Letters.2023; 2(2): 55.     CrossRef
  • Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?
    Z. Pirtošek, V. Leta, P. Jenner, M. Vérin
    Journal of Neural Transmission.2023; 130(11): 1395.     CrossRef
Multiple System Atrophy: Advances in Diagnosis and Therapy
Hirohisa Watanabe, Sayuri Shima, Yasuaki Mizutani, Akihiro Ueda, Mizuki Ito
J Mov Disord. 2023;16(1):13-21.   Published online December 20, 2022
DOI: https://doi.org/10.14802/jmd.22082
  • 3,542 View
  • 406 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDF
This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.

Citations

Citations to this article as recorded by  
  • A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism
    Kazuya Kawabata, Florian Krismer, Beatrice Heim, Anna Hussl, Christoph Mueller, Christoph Scherfler, Elke R. Gizewski, Klaus Seppi, Werner Poewe
    Movement Disorders Clinical Practice.2024; 11(4): 381.     CrossRef
  • The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy
    Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Arjun Ahluwalia, Andrew Awuah Wireko, Tomas Ferreira, Joecelyn Kirani Tan, Maximillian Wolfson, Shankhaneel Ghosh, Viktoriia Horbas, Vandana Garg, Asma Perveen, Marios Papadakis, Ghulam Md Ashraf, Ath
    CNS Neuroscience & Therapeutics.2024;[Epub]     CrossRef
Case Report
Effect of Chelation Therapy on a Korean Patient With Brain Manganese Deposition Resulting From a Compound Heterozygous Mutation in the SLC39A14 Gene
Jae-Hyeok Lee, Jin-Hong Shin
J Mov Disord. 2022;15(2):171-174.   Published online March 22, 2022
DOI: https://doi.org/10.14802/jmd.21143
  • 2,756 View
  • 184 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Mutations in the manganese transporter gene SLC39A14 lead to inherited disorders of manganese metabolism. Chelation therapy with edetate calcium disodium (CaNa2EDTA) is known to effectively reduce manganese deposition. We describe the first identified Korean case of SLC39A14-associated manganism and the treatment response to a 5-year chelation therapy. An 18-year-old female presented with childhood-onset dystonia. Magnetic resonance imaging showed T1 hyperintensity throughout the basal ganglia, brainstem, cerebellum, cerebral and cerebellar white matter, and pituitary gland. Blood manganese levels were elevated, and whole-exome sequencing revealed compound heterozygous mutations in SLC39A14. Treatment with intravenous CaNa2EDTA led to a significant reduction in serum manganese levels and T1 hyperintensities. However, her dystonia improved insignificantly. Hence, early diagnosis of this genetic disorder is essential because it is potentially treatable. Even though our treatment did not significantly reverse the establish deficits, chelation therapy could have been more effective if it was started at an earlier stage of the disease.

Citations

Citations to this article as recorded by  
  • Recent progress toward understanding the role of ZIP14 in regulating systemic manganese homeostasis
    Shannon McCabe, Kirsten Limesand, Ningning Zhao
    Computational and Structural Biotechnology Journal.2023; 21: 2332.     CrossRef
  • Metal-ion transporter SLC39A8 is required for brain manganese uptake and accumulation
    Qingli Liu, Supak Jenkitkasemwong, Tamanna Afrin Prami, Shannon Morgan McCabe, Ningning Zhao, Shintaro Hojyo, Toshiyuki Fukada, Mitchell D. Knutson
    Journal of Biological Chemistry.2023; 299(8): 105078.     CrossRef
  • Loss of slc39a14 causes simultaneous manganese hypersensitivity and deficiency in zebrafish
    Karin Tuschl, Richard J. White, Chintan Trivedi, Leonardo E. Valdivia, Stephanie Niklaus, Isaac H. Bianco, Chris Dadswell, Ramón González-Méndez, Ian M. Sealy, Stephan C. F. Neuhauss, Corinne Houart, Jason Rihel, Stephen W. Wilson, Elisabeth M. Busch-Nent
    Disease Models & Mechanisms.2022;[Epub]     CrossRef
  • Hereditary Disorders of Manganese Metabolism: Pathophysiology of Childhood-Onset Dystonia-Parkinsonism in SLC39A14 Mutation Carriers and Genetic Animal Models
    Alexander N. Rodichkin, Tomás R. Guilarte
    International Journal of Molecular Sciences.2022; 23(21): 12833.     CrossRef
  • Pathophysiological studies of aging Slc39a14 knockout mice to assess the progression of manganese-induced dystonia-parkinsonism
    Alexander N. Rodichkin, Melissa K. Edler, Jennifer L. McGlothan, Tomás R. Guilarte
    NeuroToxicology.2022; 93: 92.     CrossRef
  • Mechanisms of manganese-induced neurotoxicity and the pursuit of neurotherapeutic strategies
    Edward Pajarillo, Ivan Nyarko-Danquah, Alexis Digman, Harpreet Kaur Multani, Sanghoon Kim, Patric Gaspard, Michael Aschner, Eunsook Lee
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
Review Articles
Manganese and Movement Disorders: A Review
Dinkar Kulshreshtha, Jacky Ganguly, Mandar Jog
J Mov Disord. 2021;14(2):93-102.   Published online April 6, 2021
DOI: https://doi.org/10.14802/jmd.20123
  • 10,203 View
  • 508 Download
  • 16 Web of Science
  • 16 Crossref
AbstractAbstract PDF
Scientific and technological advances achieved with industrial expansion have led to an ever-increasing demand for heavy metals. This demand has, in turn, led to increased contamination of soil, water and air with these metals. Chronic exposure to metals may be detrimental not only to occupational workers but also to the nonoccupational population exposed to these metals. Manganese (Mn), a commonly used heavy metal, is an essential cofactor for many enzymatic processes that drive biological functions. However, it is also a potential source of neurotoxicity, particularly in the field of movement disorders. The typical manifestation of Mn overexposure is parkinsonism, which may be difficult to differentiate from the more common idiopathic Parkinson’s disease. In addition to environmental exposure to Mn, other potential etiologies causing hypermanganesemia include systemic health conditions, total parenteral nutrition and genetic mutations causing Mn dyshomeostasis. In this review, we critically analyze Mn and discuss its sources of exposure, pathophysiology and clinical manifestations. We have highlighted the global public health impact of Mn and emphasize that movement disorder specialists should record a detailed social and occupational history to ensure that a toxic etiology is not misdiagnosed as a neurodegenerative disease. In the absence of a definite therapeutic option, early diagnosis and timely institution of preventive measures are the keys to managing its toxic effects.

Citations

Citations to this article as recorded by  
  • Investigation of Heavy Metal Analysis on Medicinal Plants Used for the Treatment of Skin Cancer by Traditional Practitioners in Pretoria
    Oluwaseun Mary Oladeji, Boikanyo Genneyrolter Kopaopa, Liziwe Lizbeth Mugivhisa, Joshua Oluwole Olowoyo
    Biological Trace Element Research.2024; 202(2): 778.     CrossRef
  • The Regulation of ZIP8 by Dietary Manganese in Mice
    Suetmui Yu, Ningning Zhao
    International Journal of Molecular Sciences.2023; 24(6): 5962.     CrossRef
  • Manganese Neurotoxicity as a Stroke Mimic: A Case Report
    Mohiudeen Alikunju, Nafeesathu Misiriyyah , Shaikh Sayeed Iqbal, Maria Khan
    Cureus.2023;[Epub]     CrossRef
  • Associations of ambient manganese exposure with brain gray matter thickness and white matter hyperintensities
    Shinyoung Woo, Young Noh, Sang-Baek Koh, Seung-Koo Lee, Jung il Lee, Ho Hyun Kim, Sun- Young Kim, Jaelim Cho, Changsoo Kim
    Hypertension Research.2023; 46(8): 1870.     CrossRef
  • Manganese overexposure induces Parkinson-like symptoms, altered lipid signature and oxidative stress in C57BL/6 J mouse
    Muxue Lu, Ping Deng, Lingling Yang, Xue Wang, Xiang Mei, Chao Zhou, Mengyan Chen, Zhou Zhou, Huifeng Pi, Lichuan Wu, Zhengping Yu
    Ecotoxicology and Environmental Safety.2023; 263: 115238.     CrossRef
  • The Role of Oxidative Stress in Manganese Neurotoxicity: A Literature Review Focused on Contributions Made by Professor Michael Aschner
    David C. Dorman
    Biomolecules.2023; 13(8): 1176.     CrossRef
  • Small noncoding RNA dysregulation is implicated in manganism in a rat model of methylcyclopentadienyl manganese tricarbonyl-induced unrepaired striatum damage
    Qifeng Zhu, Fan Jiang, Yuanbo Song, Lili Lu, Fajian He, Shuqi Huang, Zhaoying Huang, Jing Yao, Ningning Lei, Jianmin Huang, Shijin Lu
    The Journal of Toxicological Sciences.2023; 48(10): 535.     CrossRef
  • Differentiating Wild and Apiary Honey by Elemental Profiling: a Case Study from Mangroves of Indian Sundarban
    Tanushree Gaine, Praveen Tudu, Somdeep Ghosh, Shouvik Mahanty, Madhurima Bakshi, Nabanita Naskar, Souparna Chakrabarty, Subarna Bhattacharya, Swati Gupta Bhattacharya, Kashinath Bhattacharya, Punarbasu Chaudhuri
    Biological Trace Element Research.2022; 200(10): 4550.     CrossRef
  • Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson’s Disease Pathogenesis: A Narrative Review
    Efthalia Angelopoulou, Yam Nath Paudel, Sokratis G. Papageorgiou, Christina Piperi
    Brain Sciences.2022; 12(2): 175.     CrossRef
  • Ayahuasca as a Decoction Applied to Human: Analytical Methods, Pharmacology and Potential Toxic Effects
    Ľuboš Nižnanský, Žofia Nižnanská, Roman Kuruc, Andrea Szórádová, Ján Šikuta, Anežka Zummerová
    Journal of Clinical Medicine.2022; 11(4): 1147.     CrossRef
  • Can therapeutic plasma exchange be life-saving in life-threatening manganese intoxication?
    Emel Uyar, Esra Gurkas, Aysel Unlusoy Aksu, Serhat Emeksiz, Cigdem Seher Kasapkara, Nadide Basak Gulleroglu, Ikbal Ok Bozkaya, Kader Karlı Oguz
    Transfusion and Apheresis Science.2022; 61(4): 103417.     CrossRef
  • Manganese‐induced parkinsonism responsive to intranasal insulin: A case report
    Mehri Salari, Masoud Etemadifar, Leila Dargahi, Neda Valian, Malihe Rezaee
    Clinical Case Reports.2022;[Epub]     CrossRef
  • The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease
    Adrianne F. Pike, Ildikò Szabò, Robert Veerhuis, Luigi Bubacco
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Effect of Chelation Therapy on a Korean Patient With Brain Manganese Deposition Resulting From a Compound Heterozygous Mutation in the SLC39A14 Gene
    Jae-Hyeok Lee, Jin-Hong Shin
    Journal of Movement Disorders.2022; 15(2): 171.     CrossRef
  • Manganese chloride (MnCl2) induced novel model of Parkinson’s disease in adult Zebrafish; Involvement of oxidative stress, neuroinflammation and apoptosis pathway
    Abhishek.P.R. Nadig, Bader Huwaimel, Ahmed Alobaida, El-Sayed Khafagy, Hadil Faris Alotaibi, Afrasim Moin, Amr Selim Abu Lila, Suman, Sahyadri. M, K.L. Krishna
    Biomedicine & Pharmacotherapy.2022; 155: 113697.     CrossRef
  • Çalışma Yaşamında Manganez Maruz Kalımının Sağlık Etkileri ve Parkinsonizm
    Zehra GÖK METİN, Abdulsamet SANDAL, Ali Naci YILDIZ
    Karaelmas İş Sağlığı ve Güvenliği Dergisi.2021; 5(2): 147.     CrossRef
Update on Current Technologies for Deep Brain Stimulation in Parkinson’s Disease
Michelle Paff, Aaron Loh, Can Sarica, Andres M. Lozano, Alfonso Fasano
J Mov Disord. 2020;13(3):185-198.   Published online August 31, 2020
DOI: https://doi.org/10.14802/jmd.20052
  • 18,557 View
  • 739 Download
  • 50 Web of Science
  • 52 Crossref
AbstractAbstract PDF
Deep brain stimulation (DBS) is becoming increasingly central in the treatment of patients with Parkinson’s disease and other movement disorders. Recent developments in DBS lead and implantable pulse generator design provide increased flexibility for programming, potentially improving the therapeutic benefit of stimulation. Directional DBS leads may increase the therapeutic window of stimulation by providing a means of avoiding current spread to structures that might give rise to stimulation-related side effects. Similarly, control of current to individual contacts on a DBS lead allows for shaping of the electric field produced between multiple active contacts. The following review aims to describe the recent developments in DBS system technology and the features of each commercially available DBS system. The advantages of each system are reviewed, and general considerations for choosing the most appropriate system are discussed.

Citations

Citations to this article as recorded by  
  • Current DBS programming
    Yıldız Değirmenci
    Deep Brain Stimulation.2024; 4: 29.     CrossRef
  • Technological developments in electric-based DBS
    Mehmet Tonge
    Deep Brain Stimulation.2024; 4: 36.     CrossRef
  • Movement disorder Deep brain stimulation Hybridization: Patient and caregiver outcomes
    Nathan Esplin, Dorian Kusyk, Seung W Jeong, Shahed Elhamdani, Khaled Abdel Aziz, Amanda Webb, Cindy Angle, Donald Whiting, Nestor D. Tomycz
    Clinical Parkinsonism & Related Disorders.2024; 10: 100234.     CrossRef
  • Deep brain stimulation of the subthalamic nucleus in Parkinson disease 2013–2023: where are we a further 10 years on?
    Andrew Brian O’Keeffe, Anca Merla, Keyoumars Ashkan
    British Journal of Neurosurgery.2024; : 1.     CrossRef
  • Preventing Sudden Cessation of Implantable Pulse Generators in Deep Brain Stimulation: A Systematic Review and Protocol Proposal
    Spencer J. Oslin, Helen H. Shi, Andrew K. Conner
    Stereotactic and Functional Neurosurgery.2024; 102(2): 127.     CrossRef
  • Janus microparticles-based targeted and spatially-controlled piezoelectric neural stimulation via low-intensity focused ultrasound
    Mertcan Han, Erdost Yildiz, Ugur Bozuyuk, Asli Aydin, Yan Yu, Aarushi Bhargava, Selcan Karaz, Metin Sitti
    Nature Communications.2024;[Epub]     CrossRef
  • Spinal Cord Stimulation for Parkinson’s Disease: A Systematic Review and Meta-Analysis of Pain and Motor Outcomes
    Can Sarica, Ajmal Zemmar, Omid Yousefi, Andrew C. Yang, Ayse Uzuner, Zhiyuan Sheng, Brendan Santyr, Nardin Samuel, Michael Colditz, Artur Vetkas, Jürgen Germann, Cletus Cheyuo, Mohammadmahdi Sabahi, Raja Niranjan Jani, Ghazaleh Darmani, Kazuaki Yamamoto,
    Stereotactic and Functional Neurosurgery.2023; 101(4): 244.     CrossRef
  • Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson's disease patients: Five-year follow-up
    Yun Su Hwang, Sungyang Jo, Seung Hyun Lee, Nayoung Kim, Mi-Sun Kim, Sang Ryong Jeon, Sun Ju Chung
    Journal of the Neurological Sciences.2023; 444: 120484.     CrossRef
  • Implementing automation in deep brain stimulation: has the time come?
    Marco Bonizzato, Alfonso Fasano
    The Lancet Digital Health.2023; 5(2): e52.     CrossRef
  • Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation
    Joshua K. Wong, Helen S. Mayberg, Doris D. Wang, R. Mark Richardson, Casey H. Halpern, Lothar Krinke, Mattia Arlotti, Lorenzo Rossi, Alberto Priori, Sara Marceglia, Ro’ee Gilron, James F. Cavanagh, Jack W. Judy, Svjetlana Miocinovic, Annaelle D. Devergnas
    Frontiers in Human Neuroscience.2023;[Epub]     CrossRef
  • Deep brain stimulation: new programming algorithms and teleprogramming
    Renato Puppi Munhoz, Ghadh Albuainain
    Expert Review of Neurotherapeutics.2023; 23(5): 467.     CrossRef
  • Impact of modeled field of view in electroconvulsive therapy current flow simulations
    Alexander Guillen, Christopher C. Abbott, Zhi-De Deng, Yu Huang, Paula Pascoal-Faria, Dennis Q. Truong, Abhishek Datta
    Frontiers in Psychiatry.2023;[Epub]     CrossRef
  • Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
    Manon Auffret, Daniel Weiss, Fabrizio Stocchi, Marc Vérin, Wolfgang H. Jost
    Journal of Neural Transmission.2023; 130(11): 1411.     CrossRef
  • Multifunctional Fiber‐Based Optoacoustic Emitter as a Bidirectional Brain Interface
    Nan Zheng, Ying Jiang, Shan Jiang, Jongwoon Kim, Guo Chen, Yueming Li, Ji‐Xin Cheng, Xiaoting Jia, Chen Yang
    Advanced Healthcare Materials.2023;[Epub]     CrossRef
  • Neurological Insights into Sleep Disorders in Parkinson’s Disease
    Subramanian Thangaleela, Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Subramanian Mariappan, Subramanian Rashmi, Thiwanya Choeisoongnern, Phakkharawat Sittiprapaporn, Chaiyavat Chaiyasut
    Brain Sciences.2023; 13(8): 1202.     CrossRef
  • Investigation of a Deep Brain Stimulator (DBS) System
    Jennifer Whitestone, Anmar Salih, Tarun Goswami
    Bioengineering.2023; 10(10): 1160.     CrossRef
  • Thirty Years of Global Deep Brain Stimulation: “Plus ça change, plus c’est la même chose”?
    Marwan Hariz, Laura Cif, Patric Blomstedt
    Stereotactic and Functional Neurosurgery.2023; 101(6): 395.     CrossRef
  • The Safety to Switch from Constant Voltage to Constant Current with a Mixed Internal Pulse Generator in Deep Brain Stimulation
    Gülşah Öztürk, Kemal Paksoy
    Annals of Indian Academy of Neurology.2023; 26(4): 507.     CrossRef
  • Advances in Deep Brain Stimulation: From Mechanisms to Applications
    Stephanie S. Sandoval-Pistorius, Mallory L. Hacker, Allison C. Waters, Jing Wang, Nicole R. Provenza, Coralie de Hemptinne, Kara A. Johnson, Melanie A. Morrison, Stephanie Cernera
    The Journal of Neuroscience.2023; 43(45): 7575.     CrossRef
  • Brain stimulation treatments in epilepsy: Basic mechanisms and clinical advances
    Thomas J. Foutz, Michael Wong
    Biomedical Journal.2022; 45(1): 27.     CrossRef
  • Neurodegenerative disorders management: state-of-art and prospects of nano-biotechnology
    Raj Kumar, Keshaw Ram Aadil, Kunal Mondal, Yogendra Kumar Mishra, David Oupicky, Seeram Ramakrishna, Ajeet Kaushik
    Critical Reviews in Biotechnology.2022; 42(8): 1180.     CrossRef
  • Sleep and circadian rhythms in Parkinson’s disease and preclinical models
    Jeremy Hunt, Elizabeth J. Coulson, Rajendram Rajnarayanan, Henrik Oster, Aleksandar Videnovic, Oliver Rawashdeh
    Molecular Neurodegeneration.2022;[Epub]     CrossRef
  • Jose Delgado: A controversial trailblazer in neuromodulation
    Nicholas D. Lorusso, Uma R. Mohan, Joshua Jacobs
    Artificial Organs.2022; 46(4): 531.     CrossRef
  • Local and distant cortical responses to single pulse intracranial stimulation in the human brain are differentially modulated by specific stimulation parameters
    Angelique C. Paulk, Rina Zelmann, Britni Crocker, Alik S. Widge, Darin D. Dougherty, Emad N. Eskandar, Daniel S. Weisholtz, R. Mark Richardson, G. Rees Cosgrove, Ziv M. Williams, Sydney S. Cash
    Brain Stimulation.2022;[Epub]     CrossRef
  • Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury
    Joshua K. Wong, Günther Deuschl, Robin Wolke, Hagai Bergman, Muthuraman Muthuraman, Sergiu Groppa, Sameer A. Sheth, Helen M. Bronte-Stewart, Kevin B. Wilkins, Matthew N. Petrucci, Emilia Lambert, Yasmine Kehnemouyi, Philip A. Starr, Simon Little, Juan Ans
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Past, Present, and Future of Deep Brain Stimulation: Hardware, Software, Imaging, Physiology and Novel Approaches
    Jessica Frey, Jackson Cagle, Kara A. Johnson, Joshua K. Wong, Justin D. Hilliard, Christopher R. Butson, Michael S. Okun, Coralie de Hemptinne
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Parkinson’s Disease Management via Wearable Sensors: A Systematic Review
    Huma Mughal, Abdul Rehman Javed, Muhammad Rizwan, Ahmad S. Almadhor, Natalia Kryvinska
    IEEE Access.2022; 10: 35219.     CrossRef
  • Conversion to Hybrid Deep Brain Stimulation System to Enable Multi‐Contact Fractionation Can be Therapeutic
    Disep I. Ojukwu, Allan R. Wang, Traci S. Hornbeck, Erika A. Lim, Jennifer Sharrard, Rohit Dhall, Vivek P. Buch, Casey H. Halpern
    Movement Disorders.2022; 37(6): 1321.     CrossRef
  • Developments in Deep Brain Stimulators for Successful Aging Towards Smart Devices—An Overview
    Angelito A. Silverio, Lean Angelo A. Silverio
    Frontiers in Aging.2022;[Epub]     CrossRef
  • Single-interface bioelectronic medicines—concept, clinical applications and preclinical data
    Cristian Sevcencu
    Journal of Neural Engineering.2022; 19(3): 031001.     CrossRef
  • Current Steering Using Multiple Independent Current Control Deep Brain Stimulation Technology Results in Distinct Neurophysiological Responses in Parkinson’s Disease Patients
    Jana Peeters, Alexandra Boogers, Tine Van Bogaert, Robin Gransier, Jan Wouters, Bart Nuttin, Myles Mc Laughlin
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Managing Intractable Symptoms of Parkinson's Disease: A Nonsurgical Approach Employing Infralow Frequency Neuromodulation
    Stella B. Legarda, P. Andreas Michas-Martin, Dana McDermott
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Directional Deep Brain Stimulation in the Treatment of Parkinson's Disease
    Akash Mishra, Ritesh A Ramdhani
    Neurology.2022; 18(1): 64.     CrossRef
  • Approach to the Treatment of Pediatric Dystonia
    Carolina Gorodetsky, Alfonso Fasano
    Dystonia.2022;[Epub]     CrossRef
  • CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics
    Tirthankar Sen, Rajkumar P. Thummer
    Neurotoxicity Research.2022; 40(5): 1597.     CrossRef
  • Encoding type, medication, and deep brain stimulation differentially affect memory-guided sequential reaching movements in Parkinson's disease
    Fabian J. David, Yessenia M. Rivera, Tara K. Entezar, Rishabh Arora, Quentin H. Drane, Miranda J. Munoz, Joshua M. Rosenow, Sepehr B. Sani, Gian D. Pal, Leonard Verhagen-Metman, Daniel M. Corcos
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Remote programming for subthalamic deep brain stimulation in Parkinson's disease
    Si Chen, Shu-jun Xu, Wei-guo Li, Teng Chen, Chao Li, Shuo Xu, Ning Yang, Yi-ming Liu
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Longevity of Deep Brain Stimulation Batteries; a Global Survey of Neurosurgeons and Neurologists
    Marwan Hariz, Gun‐Marie Hariz, Patric Blomstedt
    Movement Disorders.2021; 36(5): 1273.     CrossRef
  • Basic Tips: How Do I Start Programming Deep Brain Stimulation in Parkinson Disease Patients?
    Carolina Gorodetsky, Alfonso Fasano
    Movement Disorders Clinical Practice.2021; 8(4): 639.     CrossRef
  • Deep brain stimulation: Challenges at the tissue‐electrode interface and current solutions
    Emily Kolaya, Bonnie L. Firestein
    Biotechnology Progress.2021;[Epub]     CrossRef
  • An Update on Medical and Surgical Treatments of Parkinson’s Disease
    Dipali Nemade, Thyagarajan Subramanian, Vikram Shivkumar
    Aging and disease.2021; 12(4): 1021.     CrossRef
  • Experimental Characterization of Ferroelectric Capacitor Circuits for the Realization of Simply Designed Electroceuticals
    Yves Olsommer, Frank R. Ihmig
    Electronic Materials.2021; 2(3): 299.     CrossRef
  • Flexible vs. standard subthalamic stimulation in Parkinson disease: A double-blind proof-of-concept cross-over trial
    Derrick Soh, Ricardo Maciel, Musleh Algarni, Karlo Lizarraga, Aaron Loh, Jürgen Germann, Gavin Elias, Alexandre Boutet, Renato P. Munhoz, Suneil K. Kalia, Mojgan Hodaie, Andres M. Lozano, Alfonso Fasano
    Parkinsonism & Related Disorders.2021; 89: 93.     CrossRef
  • Telemedicine and Deep brain stimulation - Current practices and recommendations
    Vibhash D. Sharma, Delaram Safarpour, Shyamal H. Mehta, Nora Vanegas-Arroyave, Daniel Weiss, Jeffrey W. Cooney, Zoltan Mari, Alfonso Fasano
    Parkinsonism & Related Disorders.2021; 89: 199.     CrossRef
  • Subspace-based predictive control of Parkinson’s disease: A model-based study
    Mahboubeh Ahmadipour, Mojtaba Barkhordari-Yazdi, Saeid R. Seydnejad
    Neural Networks.2021; 142: 680.     CrossRef
  • Advances in Triboelectric Nanogenerators for Self‐Powered Regenerative Medicine
    Samira Parandeh, Niloofar Etemadi, Mahshid Kharaziha, Guorui Chen, Ardo Nashalian, Xiao Xiao, Jun Chen
    Advanced Functional Materials.2021;[Epub]     CrossRef
  • Implantable Pulse Generators for Deep Brain Stimulation: Challenges, Complications, and Strategies for Practicality and Longevity
    Can Sarica, Christian Iorio-Morin, David H. Aguirre-Padilla, Ahmed Najjar, Michelle Paff, Anton Fomenko, Kazuaki Yamamoto, Ajmal Zemmar, Nir Lipsman, George M. Ibrahim, Clement Hamani, Mojgan Hodaie, Andres M. Lozano, Renato P. Munhoz, Alfonso Fasano, Sun
    Frontiers in Human Neuroscience.2021;[Epub]     CrossRef
  • Microstimulation Is a Promising Approach in Achieving Better Lead Placement in Subthalamic Nucleus Deep Brain Stimulation Surgery
    Lin Shi, Shiying Fan, Tianshuo Yuan, Huaying Fang, Jie Zheng, Zunyu Xiao, Yu Diao, Guanyu Zhu, Quan Zhang, Huanguang Liu, Hua Zhang, Fangang Meng, Jianguo Zhang, Anchao Yang
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Revisiting brain stimulation in Parkinson’s disease
    Carola A. Haas
    Science.2021; 374(6564): 153.     CrossRef
  • A New Implantable Closed-Loop Clinical Neural Interface: First Application in Parkinson’s Disease
    Mattia Arlotti, Matteo Colombo, Andrea Bonfanti, Tomasz Mandat, Michele Maria Lanotte, Elena Pirola, Linda Borellini, Paolo Rampini, Roberto Eleopra, Sara Rinaldo, Luigi Romito, Marcus L. F. Janssen, Alberto Priori, Sara Marceglia
    Frontiers in Neuroscience.2021;[Epub]     CrossRef
  • Update on Parkinson's Disease Therapy
    Rebecca M Gilbert
    Neurology.2021; 17(2): 92.     CrossRef
  • Deep Brain Stimulation for Parkinson's Disease: Currents Status and Emerging Concepts
    PareshK Doshi, Deepak Das
    Neurology India.2020; 68(8): 179.     CrossRef
Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
Junghwan Shin, Han-Joon Kim, Beomseok Jeon
J Mov Disord. 2020;13(1):11-19.   Published online December 19, 2019
DOI: https://doi.org/10.14802/jmd.19057
  • 10,229 View
  • 457 Download
  • 19 Web of Science
  • 19 Crossref
AbstractAbstract PDF
α-Synuclein and tau deposition in the central nervous system is responsible for various parkinsonian syndromes, including Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. Emerging evidence has suggested that pathologic α-synuclein and tau are transmitted from cell to cell and further accelerate the aggregation of pathologic proteins in neighboring cells. Furthermore, extracellular pathologic proteins have also been reported to provoke inflammatory responses that lead to neurodegeneration. Therefore, immunotherapies targeting extracellular α-synuclein and tau have been proposed as potential disease-modifying strategies. In this review, we summarize completed phase I trials and ongoing phase II trials of immunotherapies against α-synuclein and tau and further discuss concerns and hurdles to overcome in the future.

Citations

Citations to this article as recorded by  
  • Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration
    Wen Li, Jia-Yi Li
    Translational Neurodegeneration.2024;[Epub]     CrossRef
  • Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy
    Salma M. Al-Tuwairqi, Asma A. Badrah
    AIMS Mathematics.2023; 8(1): 1800.     CrossRef
  • Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy
    Winston T. Chu, Jesse Hall, Anjela Gurrala, Alexander Becsey, Shreya Raman, Michael S. Okun, Catherine T. Flores, Benoit I. Giasson, David E. Vaillancourt, Vinata Vedam-Mai
    ACS Chemical Neuroscience.2023; 14(2): 235.     CrossRef
  • Direct digital sensing of protein biomarkers in solution
    Georg Krainer, Kadi L. Saar, William E. Arter, Timothy J. Welsh, Magdalena A. Czekalska, Raphaël P. B. Jacquat, Quentin Peter, Walther C. Traberg, Arvind Pujari, Akhila K. Jayaram, Pavankumar Challa, Christopher G. Taylor, Lize-Mari van der Linden, Titus
    Nature Communications.2023;[Epub]     CrossRef
  • Inflammation in multiple system atrophy
    Marta Leńska-Mieciek, Natalia Madetko-Alster, Piotr Alster, Leszek Królicki, Urszula Fiszer, Dariusz Koziorowski
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
    Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
    Acta Neuropathologica.2022; 143(1): 55.     CrossRef
  • Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies
    Changyoun Kim, Armine Hovakimyan, Karen Zagorski, Tatevik Antonyan, Irina Petrushina, Hayk Davtyan, Gor Chailyan, Jonathan Hasselmann, Michiyo Iba, Anthony Adame, Edward Rockenstein, Marcell Szabo, Mathew Blurton-Jones, David H. Cribbs, Anahit Ghochikyan,
    npj Vaccines.2022;[Epub]     CrossRef
  • Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
    Thuy Thi Lai, Yun Joong Kim, Hyeo-il Ma, Young Eun Kim
    Journal of Movement Disorders.2022; 15(1): 1.     CrossRef
  • Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies
    Dhanya Vijayakumar, Joseph Jankovic
    CNS Drugs.2022; 36(4): 327.     CrossRef
  • Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases
    Urmi Sengupta, Rakez Kayed
    Progress in Neurobiology.2022; 214: 102270.     CrossRef
  • Modeling the dynamics of innate immune response to Parkinson disease with therapeutic approach
    Asma Badrah, Salma Al-Tuwairqi
    Physical Biology.2022; 19(5): 056004.     CrossRef
  • Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer's disease
    Le Zhao, Dan Li, Xiaofen Qi, Kaifang Guan, Haoran Chen, Rongchun Wang, Ying Ma
    Food & Function.2022; 13(21): 10851.     CrossRef
  • Harnessing the immune system for the treatment of Parkinson’s disease
    Vinata Vedam-Mai
    Brain Research.2021; 1758: 147308.     CrossRef
  • The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease
    Katja Badanjak, Sonja Fixemer, Semra Smajić, Alexander Skupin, Anne Grünewald
    International Journal of Molecular Sciences.2021; 22(9): 4676.     CrossRef
  • Viral alpha-synuclein knockdown prevents spreading synucleinopathy
    Sindhu Menon, Rikke H Kofoed, Fadl Nabbouh, Kristiana Xhima, Yasmeen Al-Fahoum, Tammy Langman, Howard T J Mount, Lamya S Shihabuddin, S Pablo Sardi, Paul E Fraser, Joel C Watts, Isabelle Aubert, Anurag Tandon
    Brain Communications.2021;[Epub]     CrossRef
  • Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
    Somin Kwon, Michiyo Iba, Changyoun Kim, Eliezer Masliah
    Neurotherapeutics.2020; 17(3): 935.     CrossRef
  • The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
    Kyu-Young Sim, Kyeong Chan Im, Sung-Gyoo Park
    International Journal of Molecular Sciences.2020; 21(15): 5295.     CrossRef
  • Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
    Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
    Alzheimer's Research & Therapy.2020;[Epub]     CrossRef
  • New Insights Into Drug Discovery Targeting Tau Protein
    Yoshiyuki Soeda, Akihiko Takashima
    Frontiers in Molecular Neuroscience.2020;[Epub]     CrossRef
Original Articles
Less Pulsatile Levodopa Therapy (6 Doses Daily) Is Associated with a Reduced Incidence of Dyskinesia
Mark M. Lin, Robert Laureno
J Mov Disord. 2019;12(1):37-42.   Published online January 30, 2019
DOI: https://doi.org/10.14802/jmd.18046
  • 9,193 View
  • 278 Download
  • 9 Web of Science
  • 8 Crossref
AbstractAbstract PDF
Objective
To evaluate whether less pulsatile levodopa therapy (LPT) can reduce the development of levodopa-induced dyskinesia (LID).
Methods
This is a retrospective cohort study of patients with Parkinson’s disease at the movement disorders clinic of Medstar Washington Hospital Center. The study was not blinded or randomized. Patients were seen between August 2002 and August 2018. During these years, we treated patients with less pulsatile (6 doses daily) levodopa treatment to reduce LID. Occurrence of LID was recorded.
Results
Ninety-five patients with Parkinson’s disease taking levodopa were divided into two groups: 1) patients who were initially managed on LPT or who switched from traditional therapy (TT) (n = 61) (mean disease duration: 7.7 ± 4.8 years, mean levodopa duration: 5.6 ± 4.5 years and mean observation time: 4.3 ± 3.4 years), and 2) patients on TT throughout the observation period or until they developed dyskinesia (n = 34) (mean disease duration: 8.3 ± 3.8 years, mean levodopa duration: 6.2 ± 4.2 years and mean observation time: 4.1 ± 3.4 years). Three of the 61 LPT patients developed dyskinesia during the observation period. One of the patients developed dyskinesia after being switched to pulsatile doses by another doctor. In the other two, dyskinesia was minimal. In contrast to this 4.9% cumulative incidence, dyskinesia occurred in 50% (17/34) of TT patients, an incidence similar to that in published data (p < 0.001).
Conclusion
Less pulsatile levodopa with 6 daily doses was associated with a low incidence of LID. Further study of this method of treatment is warranted.

Citations

Citations to this article as recorded by  
  • Reduced Plasma Levodopa Fluctuations with More Frequent Administration of a Novel Carbidopa/Levodopa Functionally Scored Tablet
    Thomas N. Chase, Ahmad AL‐Sabbagh, Minako Koga, Kathleen Clarence‐Smith
    Clinical Pharmacology in Drug Development.2024; 13(4): 380.     CrossRef
  • Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
    Mechelle M. Lewis, Lauren J. Van Scoy, Sol De Jesus, Jonathan G. Hakun, Paul J. Eslinger, Julio Fernandez-Mendoza, Lan Kong, Yang Yang, Bethany L. Snyder, Natalia Loktionova, Sridhar Duvvuri, David L. Gray, Xuemei Huang, Richard B. Mailman
    Biomolecules.2023; 13(5): 829.     CrossRef
  • Classification of l-DOPA pharmacokinetics shapes and creating a predictive model
    Noriko Nishikawa, Hirtotaka Iwaki, Yohei Mukai, Yuji Takahashi
    Parkinsonism & Related Disorders.2023; 114: 105798.     CrossRef
  • Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
    Helga María Grétarsdóttir, Erik Widman, Anders Johansson, Dag Nyholm
    Journal of Personalized Medicine.2021; 11(8): 720.     CrossRef
  • Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
    Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska
    Journal of Clinical Medicine.2021; 10(19): 4377.     CrossRef
  • Pallidal versus subthalamic nucleus deep brain stimulation for levodopa‐induced dyskinesia
    Shi‐Ying Fan, Kai‐Liang Wang, Wei Hu, Robert S. Eisinger, Alexander Han, Chun‐Lei Han, Qiao Wang, Shimabukuro Michitomo, Jian‐Guo Zhang, Feng Wang, Adolfo Ramirez‐Zamora, Fan‐Gang Meng
    Annals of Clinical and Translational Neurology.2020; 7(1): 59.     CrossRef
  • A Stage-Based Approach to Therapy in Parkinson’s Disease
    Claudia Carrarini, Mirella Russo, Fedele Dono, Martina Di Pietro, Marianna G. Rispoli, Vincenzo Di Stefano, Laura Ferri, Filomena Barbone, Michela Vitale, Astrid Thomas, Stefano Luca Sensi, Marco Onofrj, Laura Bonanni
    Biomolecules.2019; 9(8): 388.     CrossRef
  • The Gut Microbiome: A Therapeutically Targetable Site of Peripheral Levodopa Metabolism
    Eoin Mulroy, Kailash P. Bhatia
    Movement Disorders Clinical Practice.2019; 6(7): 547.     CrossRef
Individual Therapeutic Singing Program for Vocal Quality and Depression in Parkinson’s Disease
Eun Young Han, Ji Young Yun, Hyun Ju Chong, Kyoung-Gyu Choi
J Mov Disord. 2018;11(3):121-128.   Published online August 9, 2018
DOI: https://doi.org/10.14802/jmd.17078
  • 12,601 View
  • 294 Download
  • 14 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary Material
Objective
Patients with Parkinson’s disease (PD) frequently experience depression associated with voice problems. Singing involves the use of similar muscles and the neural networks associated with vocal function and emotional response. The purpose of this study is to enhance vocal quality and depressive symptoms of patients with PD using individual singing program.
Methods
The Individual Therapeutic Singing Program for PD (ITSP-PD) was conducted by a certified music therapist. In total, nine PD patients with a subjective voice problem or depression participated in 6 sessions over 2 weeks. We measured the Maximum Phonation Time (MPT) via the Praat test, the Voice Handicap Index (VHI), the Voice-Related Quality of Life (V-RQOL) and the Geriatric Depression Scale (GDS).
Results
In total, 8 out of 9 patients completed all the sessions; 6 out of 8 patients participated in the follow-up test after 6 months. A statistically significant change in MPT (p = 0.011) was observed between the pre- and post-tests. The VHI (p = 0.035) and the GDS (p = 0.018) were significantly lower in the post-test. In the pre-, post-, and follow-up tests, the MPT (p = 0.030), V-RQOL (p = 0.008), and GDS (p = 0.009) were significantly changed.
Conclusion
The ITSP-PD based on neurological singing therapy for PD showed therapeutic possibility for vocal function and depression in patients with PD. Our findings suggest the need for a randomized study to examine the continuing positive effects of the ITSP-PD over a longer period of time.

Citations

Citations to this article as recorded by  
  • Functional data analysis of prosodic prominence in Parkinson’s disease: a pilot study
    Lauri Tavi, Nelly Penttilä
    Clinical Linguistics & Phonetics.2024; 38(1): 64.     CrossRef
  • Awareness of Dysphagia-Related Complications and Risks and the Importance of Early Intervention in Patients with Parkinson’s Disease: A Qualitative Study
    Kaifeng Yao, Lihua Wang, Lihua Zhang, Aderito Seixas
    International Journal of Clinical Practice.2023; 2023: 1.     CrossRef
  • Group singing improves both physical and psychological wellbeing in people with and without chronic health conditions: A narrative review
    Quinn Campbell, Sally Bodkin-Allen, Nicola Swain
    Journal of Health Psychology.2022; 27(8): 1897.     CrossRef
  • Defining the Therapeutic Singing Voice: Further Examination of the Everyday Singing Practices of Music Therapists
    Martina C Bingham, Elizabeth K Schwartz, Anthony Meadows
    Music Therapy Perspectives.2022; 40(1): 3.     CrossRef
  • Music affects functional brain connectivity and is effective in the treatment of neurological disorders
    Luisa Speranza, Salvatore Pulcrano, Carla Perrone-Capano, Umberto di Porzio, Floriana Volpicelli
    Reviews in the Neurosciences.2022; 33(7): 789.     CrossRef
  • Acute effects of singing on cardiovascular biomarkers
    Kamila Somayaji, Mogen Frenkel, Luai Tabaza, Alexis Visotcky, Tanya Kruse Ruck, Ernest Kwesi Ofori, Michael E. Widlansky, Jacquelyn Kulinski
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Music Therapy and Parkinson’s Disease: A Systematic Review from 2015–2020
    Manuel Joaquín Machado Sotomayor, Víctor Arufe-Giráldez, Gerardo Ruíz-Rico, Rubén Navarro-Patón
    International Journal of Environmental Research and Public Health.2021; 18(21): 11618.     CrossRef
  • The use of music as an arts-based method in migrant health research: a scoping review protocol
    Fran Garry, Sylvia Murphy Tighe, Anne MacFarlane, Helen Phelan
    HRB Open Research.2020; 3: 75.     CrossRef
  • Walking the thin white line – managing voice in the older adult
    Jacqui Allen, Anna Miles
    Speech, Language and Hearing.2019; 22(1): 25.     CrossRef
  • Music Therapy and Music-Based Interventions for Movement Disorders
    Kerry Devlin, Jumana T. Alshaikh, Alexander Pantelyat
    Current Neurology and Neuroscience Reports.2019;[Epub]     CrossRef
Psychodynamic Psychotherapy for Functional (Psychogenic) Movement Disorders
Vibhash D. Sharma, Randi Jones, Stewart A. Factor
J Mov Disord. 2017;10(1):40-44.   Published online December 27, 2016
DOI: https://doi.org/10.14802/jmd.16038
  • 12,306 View
  • 189 Download
  • 12 Web of Science
  • 12 Crossref
AbstractAbstract PDF
Objective
As the literature for the treatment of functional (psychogenic) movement disorders (FMD) is sparse, we assessed clinical outcomes in patients with FMD who underwent treatment with psychodynamic psychotherapy (PDP).
Methods
A retrospective analysis of the data of patients with FMD who were referred for PDP from 2008−2014 at Emory University Medical Center was performed.
Results
Thirty patients were included, mean age at presentation was 50 years (SD 13.9) and majority were female (27/30). Most common movement disorder was involuntary shaking/jerky movements (50%) and tremor (43%). Mean duration of symptoms was 3.2 years and mean number of PDP visits was 4.9. PDP lead to good outcomes in 10, modest in 8, and poor in 9. Three patients lost to follow up. Mean duration of symptoms between two groups (good vs. poor) was not statistically significant (p = 0.11), mean number of PDP visits showed a trend towards significance (p = 0.053). In all cases of good outcomes precipitants of the movement disorder were identified and a majority (60%) was receptive of the diagnosis and had good insight.
Conclusion
PDP lead to improvement in 60% of the patients which is encouraging as the treatment is challenging. This study supports heterogeneous causes of FMD including varied roles of past/recent events and demonstrates importance of psychological approaches such as PDP. Treatment with PDP should be considered in some patients with FMD but predicting who will respond remains a challenge. Further long term prospective studies with large sample size and placebo control are needed.

Citations

Citations to this article as recorded by  
  • Functional Tic‐Like Behaviors: A Common Comorbidity in Patients with Tourette Syndrome
    Kirsten R. Müller‐Vahl, Anna Pisarenko, Carolin Fremer, Martina Haas, Ewgeni Jakubovski, Natalia Szejko
    Movement Disorders Clinical Practice.2024; 11(3): 227.     CrossRef
  • Neuropsychiatric Treatment Approaches for Functional Neurological Disorder: A How to Guide
    Sara A. Finkelstein, Caitlin Adams, Margaret Tuttle, Aneeta Saxena, David L. Perez
    Seminars in Neurology.2022; 42(02): 204.     CrossRef
  • Functional tremor
    Petra Schwingenschuh, Alberto J. Espay
    Journal of the Neurological Sciences.2022; 435: 120208.     CrossRef
  • Psychological interventions for treating functional motor symptoms: A systematic scoping review of the literature
    Erin M. Beal, Peter Coates, Cara Pelser
    Clinical Psychology Review.2022; 94: 102146.     CrossRef
  • Living with functional movement disorders: a tale of three battles. An interpretative phenomenological analysis
    Sylwia Bazydlo, Fiona J. R. Eccles
    Psychology & Health.2022; : 1.     CrossRef
  • Management of Functional Seizures and Functional Movement Disorder: A Cross-Sectional Comparative Study
    Bruno Gabriel Dal Pasquale, Hélio Afonso Ghizoni Teive, Marcelo Daudt von der Heyde, Luana Francine Anad Dal Pasquale
    Neuropsychiatric Disease and Treatment.2022; Volume 18: 2121.     CrossRef
  • Efficacy of a 5-day, intensive, multidisciplinary, outpatient physical and occupational therapy protocol in the treatment of functional movement disorders: A retrospective study
    Megan Reid, Steven D. Mitchell, Katharine M. Mitchell, Christos Sidiropoulos
    Journal of the Neurological Sciences.2022; 443: 120461.     CrossRef
  • Diagnosis and therapy of functional tremor a systematic review illustrated by a case report
    Michael Bartl, Rebekka Kewitsch, Mark Hallett, Martin Tegenthoff, Walter Paulus
    Neurological Research and Practice.2020;[Epub]     CrossRef
  • Speech, language and swallowing impairments in functional neurological disorder: a scoping review
    Caroline Barnett, Jean Armes, Christina Smith
    International Journal of Language & Communication Disorders.2019; 54(3): 309.     CrossRef
  • Functional movement disorders in neurogeriatric inpatients
    Sara Mätzold, Johanna Geritz, Kirsten E. Zeuner, Daniela Berg, Steffen Paschen, Johanne Hieke, Simone Sablowsky, Christian Ortlieb, Philipp Bergmann, Werner Hofmann, Alberto J. Espay, Walter Maetzler
    Zeitschrift für Gerontologie und Geriatrie.2019; 52(4): 324.     CrossRef
  • Psychogenic (Functional) Movement Disorders
    Mary Ann Thenganatt, Joseph Jankovic
    CONTINUUM: Lifelong Learning in Neurology.2019; 25(4): 1121.     CrossRef
  • Disentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future
    Karen S. Rommelfanger, Stewart A. Factor, Suzette LaRoche, Phyllis Rosen, Raymond Young, Mark H. Rapaport
    Frontiers in Neurology.2017;[Epub]     CrossRef
Review Articles
Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders
Wooseok Im, Jangsup Moon, Manho Kim
J Mov Disord. 2016;9(3):136-143.   Published online September 21, 2016
DOI: https://doi.org/10.14802/jmd.16029
  • 20,572 View
  • 622 Download
  • 14 Web of Science
  • 10 Crossref
AbstractAbstract PDF
Gene therapy is a potential therapeutic strategy for treating hereditary movement disorders, including hereditary ataxia, dystonia, Huntington’s disease, and Parkinson’s disease. Genome editing is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome using modified nucleases. Recently, clustered regularly interspaced short palindromic repeat/CRISPR associated protein 9 (CRISPR/Cas9) has been used as an essential tool in biotechnology. Cas9 is an RNA-guided DNA endonuclease enzyme that was originally associated with the adaptive immune system of Streptococcus pyogenes and is now being utilized as a genome editing tool to induce double strand breaks in DNA. CRISPR/Cas9 has advantages in terms of clinical applicability over other genome editing technologies such as zinc-finger nucleases and transcription activator-like effector nucleases because of easy in vivo delivery. Here, we review and discuss the applicability of CRISPR/Cas9 to preclinical studies or gene therapy in hereditary movement disorders.

Citations

Citations to this article as recorded by  
  • Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease
    Young Cha, Tae-Yoon Park, Pierre Leblanc, Kwang-Soo Kim
    Journal of Movement Disorders.2023; 16(1): 22.     CrossRef
  • Crispr-a novel approach towards a fortified immune system
    Vasudevan Ranganathan, Padma Madham, Prerana Shankpal, Charitha Sheri
    Journal of Microbiology & Experimentation.2023; 11(3): 73.     CrossRef
  • Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases
    Della Grace Thomas Parambi, Khalid Saad Alharbi, Rajesh Kumar, Seetha Harilal, Gaber El-Saber Batiha, Natália Cruz-Martins, Omnia Magdy, Arafa Musa, Dibya Sundar Panda, Bijo Mathew
    Molecular Neurobiology.2022; 59(1): 191.     CrossRef
  • Effects of the timing of electroporation during in vitro maturation on triple gene editing in porcine embryos using CRISPR/Cas9 system
    Zhao Namula, Manita Wittayarat, Lanh Thi Kim Do, Thanh Van Nguyen, Qingyi Lin, Koki Takebayashi, Maki Hirata, Fuminori Tanihara, Takeshige Otoi
    Veterinary and Animal Science.2022; 16: 100241.     CrossRef
  • Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications
    Precilla S. Daisy, Kuduvalli S. Shreyas, T. S. Anitha
    Molecular Biotechnology.2021; 63(2): 93.     CrossRef
  • The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing
    Parichehr Hassanzadeh
    Life Sciences.2021; 274: 119289.     CrossRef
  • CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models
    Mahdi Barazesh, Shiva Mohammadi, Yadollah Bahrami, Pooneh Mokarram, Mohammad Hossein Morowvat, Massoud Saidijam, Morteza Karimipoor, Soudabeh Kavousipour, Amir Reza Vosoughi, Korosh Khanaki
    Current Gene Therapy.2021; 21(2): 130.     CrossRef
  • La edición del ADN
    Ithzayana Madariaga-Perpiñan, Juan Camilo Duque-Restrepo, Paola Ayala-Ramirez, Reggie García-Robles
    Iatreia.2020; 33(3): 262.     CrossRef
  • Mucuna pruriens in Parkinson’s and in some other diseases: recent advancement and future prospective
    Sachchida Nand Rai, Vivek K. Chaturvedi, Payal Singh, Brijesh Kumar Singh, M. P. Singh
    3 Biotech.2020;[Epub]     CrossRef
  • Current Approaches to the Treatment of Hunter Syndrome
    Ekaterina Yu. Zakharova, Elena Yu. Voskoboeva, Alla N. Semyachkina, Nato D. Vashakmadze, Amina I. Gamzatova, Svetlana V. Mikhailova, Sergey I. Kutsev
    Pediatric pharmacology.2018; 15(4): 324.     CrossRef
Mechanism of Anti-α-Synuclein Immunotherapy
Jun Sung Lee, Seung-Jae Lee
J Mov Disord. 2016;9(1):14-19.   Published online January 25, 2016
DOI: https://doi.org/10.14802/jmd.15059
  • 25,477 View
  • 332 Download
  • 35 Web of Science
  • 35 Crossref
AbstractAbstract PDF
Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.

Citations

Citations to this article as recorded by  
  • Aggregation-Induced Emission Luminogens: A New Possibility for Efficient Visualization of RNA in Plants
    Zheng-Chao Yang, Li-Xiang Zhao, Yu-Qi Sang, Xin Huang, Xuan-Chen Lin, Zhi-Ming Yu
    Plants.2024; 13(5): 743.     CrossRef
  • Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
    Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
    Acta Neuropathologica.2022; 143(1): 55.     CrossRef
  • Autophagy-Related Pathways in Vesicular Unconventional Protein Secretion
    Shin Hye Noh, Ye Jin Kim, Min Goo Lee
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease
    Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernandez-Diaz, Sandra-Fausia Soukup
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant
    Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi, Hugo Geerts
    Journal of Pharmacokinetics and Pharmacodynamics.2022; 49(6): 593.     CrossRef
  • Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
    Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal, Pallab Bhattacharya
    Immunology.2021; 162(2): 160.     CrossRef
  • Electrogastrography for diagnosis of early-stage Parkinson's disease
    Nobuyuki Araki, Yoshitaka Yamanaka, Anupama Poudel, Yoshikatsu Fujinuma, Akira Katagiri, Satoshi Kuwabara, Masato Asahina
    Parkinsonism & Related Disorders.2021; 86: 61.     CrossRef
  • Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
    Simona S. Ghanem, Hend S. Fayed, Qi Zhu, Jia-Hong Lu, Nishant N. Vaikath, Janarthanan Ponraj, Said Mansour, Omar M. A. El-Agnaf
    Molecules.2021; 26(12): 3736.     CrossRef
  • Tat-p27 Ameliorates Neuronal Damage Reducing α-Synuclein and Inflammatory Responses in Motor Neurons After Spinal Cord Ischemia
    Woosuk Kim, Hyun Jung Kwon, Hyo Young Jung, Kyu Ri Hahn, Seung Myung Moon, Yeo Sung Yoon, In Koo Hwang, Soo Young Choi, Dae Won Kim
    Neurochemical Research.2021; 46(12): 3123.     CrossRef
  • Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
    Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling, Rhun Yian Koh
    CNS & Neurological Disorders - Drug Targets.2021; 20(9): 802.     CrossRef
  • Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
    Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker
    Pharmacological Reviews.2021; 73(4): 1204.     CrossRef
  • Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
    Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
    Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova
    Translational Neurodegeneration.2020;[Epub]     CrossRef
  • Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation
    James H. Torpey, Richard M. Meade, Ravina Mistry, Jody M. Mason, Jillian Madine
    Frontiers in Neuroscience.2020;[Epub]     CrossRef
  • Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
    Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
    Alzheimer's Research & Therapy.2020;[Epub]     CrossRef
  • Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
    Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E. Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar
    Molecular Neurobiology.2019; 56(7): 4799.     CrossRef
  • The Associations between Immunological Reactivity to the Haptenation of Unconjugated Bisphenol A to Albumin and Protein Disulfide Isomerase with Alpha-Synuclein Antibodies
    Datis Kharrazian, Martha Herbert, Aristo Vojdani
    Toxics.2019; 7(2): 26.     CrossRef
  • Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model
    Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Anthony Adame, Changyoun Kim, Radmila Santic, Achim Schneeberger, Frank Mattner, Sabine Schmidhuber, Gergana Galabova, Brian Spencer, Eliezer Masliah, Robert A. Rissman
    Alzheimer's & Dementia.2019; 15(9): 1133.     CrossRef
  • Translational therapies for multiple system atrophy: Bottlenecks and future directions
    Nadia Stefanova
    Autonomic Neuroscience.2018; 211: 7.     CrossRef
  • Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway
    Liyan Hou, Xiuqi Bao, Caixia Zang, Hanyu Yang, Fuqiang Sun, Yuning Che, Xuefei Wu, Shao Li, Dan Zhang, Qingshan Wang
    Redox Biology.2018; 14: 600.     CrossRef
  • Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood
    Isabell Kuhn, Tobias Rogosch, Theresa I. Schindler, Björn Tackenberg, Michael Zemlin, Rolf F. Maier, Richard Dodel, Yannick Kronimus
    Journal of Neuroimmunology.2018; 315: 33.     CrossRef
  • Beneficial Effects of Flavonoids Against Parkinson's Disease
    Un Ju Jung, Sang Ryong Kim
    Journal of Medicinal Food.2018; 21(5): 421.     CrossRef
  • Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases
    Jiyoon Kim, Heon Yung Gee, Min Goo Lee
    Journal of Cell Science.2018;[Epub]     CrossRef
  • Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
    Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson, Fredrik Eriksson, Jessica Sigvardson, Werner Poewe, Gregor K. Wenning, Eva Nordström, Nadia Stefanova
    Frontiers in Neuroscience.2018;[Epub]     CrossRef
  • Gene therapy for neurological disorders: progress and prospects
    Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul, Dinah W. Y. Sah
    Nature Reviews Drug Discovery.2018; 17(9): 641.     CrossRef
  • Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
    Edward Rockenstein, Gary Ostroff, Fusun Dikengil, Florentina Rus, Michael Mante, Jazmin Florio, Anthony Adame, Ivy Trinh, Changyoun Kim, Cassia Overk, Eliezer Masliah, Robert A. Rissman
    The Journal of Neuroscience.2018; 38(4): 1000.     CrossRef
  • Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
    Julianna J. Tomlinson, Bojan Shutinoski, Li Dong, Fanyi Meng, Dina Elleithy, Nathalie A. Lengacher, Angela P. Nguyen, Greg O. Cron, Qiubo Jiang, Erik D. Roberson, Robert L. Nussbaum, Nour K. Majbour, Omar M. El-Agnaf, Steffany A. Bennett, Diane C. Lagace,
    Journal of Neural Transmission.2017; 124(6): 721.     CrossRef
  • Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease
    Xiaoli Si, Jiali Pu, Baorong Zhang
    Journal of Movement Disorders.2017; 10(2): 69.     CrossRef
  • Membrane Trafficking Illuminates a Path to Parkinson’s Disease
    Takafumi Hasegawa, Naoto Sugeno, Akio Kikuchi, Toru Baba, Masashi Aoki
    The Tohoku Journal of Experimental Medicine.2017; 242(1): 63.     CrossRef
  • Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
    J. Teister, F. Anders, S. Beck, S. Funke, H. von Pein, V. Prokosch, N. Pfeiffer, F. Grus
    Scientific Reports.2017;[Epub]     CrossRef
  • Impact of aging immune system on neurodegeneration and potential immunotherapies
    Zhanfeng Liang, Yang Zhao, Linhui Ruan, Linnan Zhu, Kunlin Jin, Qichuan Zhuge, Dong-Ming Su, Yong Zhao
    Progress in Neurobiology.2017; 157: 2.     CrossRef
  • A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
    Jess-Karan S. Dhillon, Cara Riffe, Brenda D. Moore, Yong Ran, Paramita Chakrabarty, Todd E. Golde, Benoit I. Giasson, Stephan N. Witt
    PLOS ONE.2017; 12(9): e0184731.     CrossRef
  • Vaccination strategies in tauopathies and synucleinopathies
    Anne K. Braczynski, Jörg B. Schulz, Jan‐Philipp Bach
    Journal of Neurochemistry.2017; 143(5): 467.     CrossRef
  • Missions of <italic>Journal of Movement Disorders</italic>
    Yun Joong Kim
    Journal of Movement Disorders.2016; 9(1): 1.     CrossRef
  • How strong is the evidence that Parkinson's disease is a prion disorder?
    Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower
    Current Opinion in Neurology.2016; 29(4): 459.     CrossRef
Cell Therapy Strategies vs. Paracrine Effect in Huntington’s Disease
Wooseok Im, Manho Kim
J Mov Disord. 2014;7(1):1-6.   Published online April 30, 2014
DOI: https://doi.org/10.14802/jmd.14001
  • 14,006 View
  • 88 Download
  • 6 Web of Science
  • 5 Crossref
AbstractAbstract PDF
Huntington’s disease (HD) is a genetic neurodegenerative disorder. The most common symptom of HD is abnormal involuntary writhing movements, called chorea. Antipsychotics and tetrabenazine are used to alleviate the signs and symptoms of HD. Stem cells have been investigated for use in neurodegenerative disorders to develop cell therapy strategies. Recent evidence indicates that the beneficial effects of stem cell therapies are actually mediated by secretory molecules, as well as cell replacement. Although stem cell studies show that cell transplantation provides cellular improvement around lesions in in vivo models, further work is required to elucidate some issues before the clinical application of stem cells. These issues include the precise mechanism of action, delivery method, toxicity and safety. With a focus on HD, this review summarizes cell therapy strategies and the paracrine effect of stem cells.

Citations

Citations to this article as recorded by  
  • Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases
    Dongkyu Kim, Gun-Sik Cho, Choongseong Han, Dong-Hyuk Park, Hee-Kyung Park, Dong-Hun Woo, Jong-Hoon Kim
    Tissue Engineering and Regenerative Medicine.2017; 14(6): 653.     CrossRef
  • Induced Pluripotent Stem Cells in Huntington’s Disease: Disease Modeling and the Potential for Cell-Based Therapy
    Ling Liu, Jin-Sha Huang, Chao Han, Guo-Xin Zhang, Xiao-Yun Xu, Yan Shen, Jie Li, Hai-Yang Jiang, Zhi-Cheng Lin, Nian Xiong, Tao Wang
    Molecular Neurobiology.2016; 53(10): 6698.     CrossRef
  • Stem Cells in Neurological Disorders: Emerging Therapy with Stunning Hopes
    Ghanshyam Upadhyay, Sharmila Shankar, Rakesh K. Srivastava
    Molecular Neurobiology.2015; 52(1): 610.     CrossRef
  • Genome Modification Leads to Phenotype Reversal in Human Myotonic Dystrophy Type 1 Induced Pluripotent Stem Cell-Derived Neural Stem Cells
    Guangbin Xia, Yuanzheng Gao, Shouguang Jin, S.H. Subramony, Naohiro Terada, Laura P.W. Ranum, Maurice S. Swanson, Tetsuo Ashizawa
    Stem Cells.2015; 33(6): 1829.     CrossRef
  • Glycogen synthase kinase 3β inhibition enhanced proliferation, migration and functional re-endothelialization of endothelial progenitor cells in hypercholesterolemia microenvironment
    Bin Cui, Jun Jin, Xiaohan Ding, Mengyang Deng, Shiyong Yu, MingBao Song, Yang Yu, Xiaohui Zhao, Jianfei Chen, Lan Huang
    Experimental Biology and Medicine.2015; 240(12): 1752.     CrossRef

JMD : Journal of Movement Disorders